KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other Non-Current Liabilities: 2009-2024

Historic Other Non-Current Liabilities for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Dec 2024 value amounting to $40.0 million.

  • Rigel Pharmaceuticals' Other Non-Current Liabilities changed negligibly% to $40.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $40.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $40.0 million for FY2024, which is 0.09% up from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Other Non-Current Liabilities of $40.0 million as of FY2024, which was up 0.09% from $39.9 million recorded in FY2023.
  • Rigel Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $52.7 million for FY2021, and its period low was $5.0 million during FY2020.
  • Its 3-year average for Other Non-Current Liabilities is $40.7 million, with a median of $40.0 million in 2024.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Other Non-Current Liabilities skyrocketed by 945.13% in 2021, and later dropped by 19.84% in 2022.
  • Yearly analysis of 5 years shows Rigel Pharmaceuticals' Other Non-Current Liabilities stood at $5.0 million in 2020, then soared by 945.13% to $52.7 million in 2021, then fell by 19.84% to $42.3 million in 2022, then dropped by 5.49% to $39.9 million in 2023, then grew by 0.09% to $40.0 million in 2024.